Breast Cancer Drug Resistance Mechanism Identified in Houston
Houston researchers found a signaling pathway that may limit how well T-DXd works for metastatic breast cancer.
Updated on Oct. 1, 2026 in Cancer
Live Poll
Should medical researchers prioritize testing existing drugs in new combinations to overcome treatment resistance?
Houston Methodist researchers discovered that activation of the S100-RAGE signaling pathway may prevent T-DXd from effectively treating certain metastatic breast cancers. The findings, which suggest a path toward overcoming drug resistance, are currently being investigated in a new clinical study.
Why it matters
Understanding why HER2-expressing tumors stop responding to T-DXd is critical for improving patient outcomes. This research explores whether blocking this pathway could restore treatment sensitivity for those whose cancer has stopped responding to standard therapy.
In an analysis of 109 metastatic lesions from 47 patients, researchers used spatial transcriptomic and proteomic profiling to identify elevated S100A7, S100A9, and S100P protein expression in T-DXd-resistant tumors. These preliminary laboratory results identified the S100-RAGE pathway as a key factor.
The players
Houston Methodist
A Texas-based academic medical center conducting research into metastatic breast cancer therapies and resistance mechanisms.
The details
Researchers utilized spatial transcriptomic and proteomic profiling to examine how genes and proteins interact within the tumor microenvironment. By mapping these specific cell neighborhoods, they discovered that activating the S100-RAGE signaling pathway blocks T-DXd's effectiveness. Laboratory and animal model tests showed that inhibiting RAGE, using the compound TTP488 alongside T-DXd, successfully reduced metastatic tumor burden.
Timeline
October 1, 2026: Findings were published regarding the S100-RAGE signaling pathway.
Health Landscape
This research expands the understanding of resistance to the HER2-targeted therapy T-DXd, which has become a significant tool in treating metastatic breast cancer. It follows an evolving trend of using spatial mapping to move beyond general tumor characteristics to address site-specific treatment failure.
Patients currently receiving T-DXd for metastatic breast cancer who have concerns about treatment response should discuss these findings with their oncologist. These results are preliminary and are currently being evaluated in a clinical study to determine future potential treatment options.
The takeaway
While promising, this research is in the early stages and does not change current care plans. Patients should continue their prescribed therapies and consult their physician regarding any questions about drug resistance or new clinical trial enrollments.
Further reading
For broader information on current developments in oncological research, visit the Cancer section.
Source note: This article includes information reported by U.S. News & World Report.
Live Poll
Should medical researchers prioritize testing existing drugs in new combinations to overcome treatment resistance?
